G lioblastoma (GBM) is the most common type of primary malignant brain tumor in adults. 26 Although combined treatment with radiotherapy and temozolomide improves the 5-year survival rate, 40 median overall survival remains around 14.6 months and the 5-year survival rate is only 9.8% at present. 40 Aggressive resection of the tumor can improve the survival rate.
that human bone marrow-derived mesenchymal stem cells (hMSCs) administered by intravenous, intraarterial, or intracranial injection show tropism for human intracranial U87 gliomas in mice. 33 We also demonstrated that compared with hMSCs transfected with a control plasmid, hMSCs transfected with interferon b significantly increased the survival of mice bearing intracranial U87 gliomas. 33 MicroRNAs (miRNAs) are a newly discovered class of small noncoding RNA molecules that posttranscriptionally regulate a broad spectrum of gene expression. 2, 4 Recently, some miRNAs have been reported to suppress the invasiveness of malignant gliomas, [29] [30] [31] 35 and these findings suggest that treatment with miRNAs has the potential to become a novel therapy for GBM. However, ideal systems for the delivery of miRNAs to the target tissue remain in the developmental stage. 29, 30 hMSCs secrete microvesicles, or exosomes, containing miRNAs. 43 miRNAs secreted from host cells can be transferred to recipient cells through contact-dependent and/or contact-independent mechanisms and can alter the function of the recipient cell. 19, 34, 42 Munoz et al. demonstrated that anti-mir-9 delivered by hMSCs is transferred to GBM cells in a contact-dependent manner and reduces the resistance of GBM cells to temozolomide. 32 Thus, hMSCs have the potential to become delivery vehicles for miRNAs to malignant gliomas. However, transfection with miRNAs can affect the tropism of hMSCs for malignant glioma cells.
In this study, we investigated the ability of miRNAs to inhibit the invasion of hMSCs by glioma cells without altering the tropism of hMSCs for glioma cells. We also observed the effects of miRNAs that were overexpressed in hMSCs to determine if alteration of the function of glioma cells in a contact-dependent manner occurred in vivo and ex vivo, results that may suggest that hMSCs could be used as delivery vehicles for miRNAs that may be useful in the treatment of GBM.
Methods

Cell Lines and Culture
The GBM cell lines U87, U251, and LN229 were obtained from the American Type Culture Collection. The hMSCs were obtained from Lonza Japan. U87, U251, and LN229 cells were maintained in alpha minimum essential medium (a-MEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) and a 1% penicillin-streptomycin mixture (Wako). The hMSCs were maintained in a-MEM supplemented with 20% FBS (Invitrogen), 1% lglutamine (Gibco), and a 1% penicillin-streptomycin mixture (Wako). Cells were incubated at 37°C in a humidified atmosphere containing 5% CO 2 and 95% air.
Extraction of Cellular or Exosomal miRNAs From U87 Cells and hMSCs
To obtain purified total RNA for analysis, we extracted cellular miRNAs from U87 cells and exosomal miRNAs from hMSCs.
Cellular miRNAs were extracted using the mirVana miRNA isolation kit (Ambion) according to the manufacturer's protocols. The purified total RNA was eluted in a 100-μl elution buffer.
Exosomal miRNAs were extracted as follows. Briefly, after the cells reached subconfluence (70%-80% confluence), the medium was replaced with serum-free a-MEM. Forty-eight hours after incubation, 10 ml culture supernatant was collected and centrifuged at 3000g for 15 minutes to remove cells and debris. To extract the exosomes, the supernatant was mixed with 2 ml ExoQuick-TC reagent (Systems Biosciences) and stored at 4°C for 12 hours. The mixture of the sample and ExoQuick-TC reagent was centrifuged at 1500g for 30 minutes at 25°C, and the obtained exosome pellets were stored at -80°C. miRNAs were extracted from the exosome pellets using the Total Exosome RNA and Protein Isolation Kit (Invitrogen) according to the manufacturer's protocols. The purified total RNA was eluted in 100 μl elution buffer.
The total RNA was quantified with NanoDrop 2000c (Thermo Fisher Scientific), and RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies).
Analysis Procedures for Cellular and Exosomal miRNA Expression in U87 Cells and hMSCs
The purified total RNA (50 ng) was reverse transcribed in 10-ml reactions using the miRCURY LNA Universal RT miRNA polymerase chain reaction (PCR) protocol and complementary DNA (cDNA) synthesis kit (Exiqon). Each reverse-transcribed reaction was spiked with artificial RNA (UniSp6). cDNA was diluted 50 times and assayed in 10-ml PCR mixtures according to the manufacturer's protocol. Amplification was performed using the LightCycler 480 Real-Time PCR System (Roche) on a Human miRNome microRNA ready-to-use PCR Panel I+II (V3.R) (Takara), which contained 752 mature miRNA sequences. The amplification curves were analyzed using Roche LC software, both for determination of the quantitation cycle (Cq) (with the second derivative method) and for melting curve analysis. NormFinder (MOMA) 3 was used to select hsa-miR-23a-3p, hsa-miR-320a, and hsamiR-222-3p as the optimal genes for normalization, and the relative expression (DCq) of each miRNA investigated in this study was normalized to these 3 genes. The relative expression ratios between U87 cellular miRNAs and hMSC exosomal miRNAs were calculated using the following formula: relative expression ratio = (DCq of hMSC exosomal miRNAs) -(DCq of U87 cellular miRNAs).
MicroRNA Transfection
In all of the experiments, the miRNAs transfected into the cells (GBM U87, U251, and LN229 cells and hMSCs) were human mirVana miRNA mimics (Thermo Fisher Scientific). Before transfection, the U87, U251, and LN229 cells were seeded onto 24-well plates at a density of 5 × 10 4 cells/well, and hMSCs were seeded onto 6-well plates at a density of 5 × 10 4 cells/well. After overnight incubation at 37°C, depending on the experimental protocol, the GBM and the hMSC cells were transfected with 1 or 2 or 3 miRNA mimics among 9 different human mirVana miRNA mimics (hsa-miR-154-5p, -409-3p, -127-3p, -193a-5p, -145-5p, -145-3p, -143-3p, -196a-5p, or -31-5p) or mirVana miRNA mimic negative control 1 (Ambion) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocols. Briefly, we diluted 1 μl of 10 μM miRNA mimics or the miRNA-negative control in 50 ml Opti-Mem and 3 ml Lipofectamine RNAiMAX in 50 ml Opti-MEM. These were mixed gently and incubated for 5 minutes at room temperature. Then, the oligomer-Lipofectamine RNAiMAX complexes were added to each well at a final concentration of 10 nM. Cotransfection of 2 or 3 miRNAs was performed at a final concentration of 10 nM for each well, for a total of 20 or 30 nM, respectively. To transport the miRNA from hMSCs to U87 cells, the hMSCs were also transfected for 24 hours with customdesigned Alexa555-labeled PremiR precursor miRNA (Life Technologies) and hsa-miR-145-5p or hsa-miR-31-5p.
Collection of Conditioned Medium
U87, U251, and LN229 cells and hMSCs were transfected with miRNAs and incubated overnight. After the cells were washed 3 times with phosphate-buffered saline (PBS), the medium was replaced with fresh, serum-free a-MEM. After 48 hours of incubation, the resulting medium was aspirated and centrifuged at 3000g for 15 minutes to remove cells and debris.
Matrigel Invasion Assay
Cell invasion was analyzed using BD BioCoat Matrigel Invasion Chambers (24-well plates with 8-mm pores; BD Biosciences) according to the manufacturer's protocols. Briefly, the invasion chamber was rehydrated with serumfree a-MEM at 37°C in a 5% CO 2 incubator for 2 hours. After rehydration, U87 cells, hMSCs, or a mixture of U87 cells and hMSCs at a 1:1 ratio were placed at a density of 5.0 × 10 4 cells/ml in 500 μl serum-free medium on the upper wells of the Transwell plates. For the invasion assay with the U87 cells or the mixture, a-MEM supplemented with 10% FBS was added to the lower wells of the Transwell plates. For the tropism assay of the hMSCs, the conditioned medium obtained from the U87 cells was added to the lower wells. The invasion chamber with the U87 cells was incubated for 24 hours, or the hMSCs and the mixture were incubated for 48 hours. The noninvading cells on the upper surface of the membrane of the upper wells were removed, and the invading cells on the lower surface of the membrane were stained with a Quick-Diff stain kit (Becton Dickinson). After being washed twice with water, the chambers were allowed to air dry. The invading cells were observed under a microscope (Biozero-8000, Keyence). The membrane was divided into quarters, and the number of invading cells in each field was counted at ×200 magnification (field area 0.58 mm 2 ) and averaged. All assays were carried out in triplicate. The same protocol was performed using U251 and LN229 cells.
Visualization of miRNA Transportation From hMSCs to U87 Cells
The U87 cells were labeled with Vybrant DiO (Invitrogen) according to the manufacturer's protocols. Briefly, the U87 cells were incubated with 2.5 ml/ml Vybrant DiO cell solution for 30 minutes and protected from light at 37°C in a humidified atmosphere containing 5% CO 2 . After the cells were washed 3 times with PBS, the dye solution was replaced with fresh medium. The hMSCs were transfected with custom-designed Alexa555-labeled PremiR precursor miRNA, as described above. After 24 hours of transfection, the Alexa555-labeled miRNA-transfected hMSCs were thoroughly washed 5 times to remove the residual miRNAs and the transfection reagent. Vybrant DiO-labeled U87 cells were added at a ratio of 1:1 to the Alexa555-labeled miRNA-transfected hMSCs. Twenty-four hours after incubation, the cells were observed by using fluorescence microscopy (Biozero-8000).
Preparation of Organotypic Brain Slice Cultures
To investigate the abilities of the U87 cells to invade hMSCs in brain tissues, an invasion assay using organotypic brain slice cultures was performed as previously described with modifications.
1,17,18,39 Twelve 2-day-old Sprague-Dawley rats (Kyudo) were decapitated under pentobarbital anesthesia (150 mg/kg intraperitoneal injection). The brains were removed and immediately immersed in Hanks' balanced salt solution (Gibco). The brains were then cut coronally into 250-mm-thick slices using a McIlwain tissue chopper (Mickle Laboratory Engineering). The brain slice cultures were placed on sterile, porous (0.4-mm) insert membranes (Millipore) and transferred to 6-well plates (BD Falcon). The slices were cultivated at 37°C in a humidified atmosphere with 5% CO 2 in standard medium consisting of DMEM/Ham's F12 (pH 7.3) (Gibco), 24% normal horse serum (Invitrogen), 1% penicillin-streptomycin (Wako), 1% amphotericin B (Sigma-Aldrich), 1% N2 supplement (Gibco), and additional 10 mM d-glucose (Sigma-Aldrich). The medium was changed every other day.
Hanging Drop Cell Culture
Before implantation of the U87 cells and hMSCs into the organotypic brain slice cultures described above, a hanging drop protocol was used to generate cell aggregates of the U87 and hMSC cells as previously described. 9 Briefly, hMSCs were cotransfected with 2 miRNA mimics (hsa-miR-145-5p and -31-5p) or the negative control and were incubated with 2.5 ml/ml Vybrant DiI cell solution (Invitrogen) for 30 minutes while protected from light at 37°C in a humidified atmosphere with 5% CO 2 . After the cell aggregates were washed 3 times with PBS, the dye solution was replaced with fresh medium. Green fluorescent protein (GFP)-expressing U87 cells were purchased from AntiCancer Japan. A mixed-cell population containing the GFP-expressing U87 cells and Vybrant DiI-labeled hMSCs at a 1:1 ratio was adjusted to a density of 2.5 × 10 6 cells/ml in a-MEM containing 20% FBS (Invitrogen), 1% l-glutamine (Gibco), and a 1% penicillin-streptomycin mixture (Wako). The lid of a 6-cm tissue culture dish was removed, and 20 ml of the medium containing the cells was deposited onto the bottom of the lid. Five milliliters of PBS was placed in the bottom of the dish to create a hydration chamber. The lid was inverted onto the PBS-filled bottom chamber and incubated at 37°C in a humidified atmosphere with 5% CO 2 . After 24 hours, the cell aggregates were observed under a microscope (Biozero-8000).
Assessment of the Invasive Area of U87 Cells Using Organotypic Brain Slice Cultures
After the brain slices were allowed to equilibrate in the medium for 4 hours, a 1-mm-diameter hole was made in the striatum of each brain slice with a micropipette tip. The cell aggregates of the mixed-cell population containing GFP-expressing U87 cells and Vybrant DiI-labeled hMSCs were placed in the hole of the brain slice and incubated for 4 days. The invasion of GFP-expressing U87 cells was monitored using fluorescence microscopy (Biozero-8000) 2 and 4 days after implantation. The area containing GFP-expressing U87 cells was measured using the software included with the BZ analyzer (Keyence). The extent of invasion was calculated as the relative invasive area, i.e., the ratio of the invaded areas on days 2 and 4 to the area on day 0, and the area of the cell aggregates on the day of implantation was assigned a value of 100%. High-magnification photomicrographs were obtained using a confocal laser scanning microscope (A1 inverted confocal microscope, Nikon).
Assessment of the Number of Cells in Aggregates Containing U87 Cells and hMSCs Transfected With miRNA Mimics or the Negative Control
Cell aggregates containing U87 cells and hMSCs transfected with the miRNA mimics or the negative control were placed in 6-well plates (BD Falcon) in a humidified atmosphere containing 5% CO and cultivated at 37°C in standard medium consisting of DMEM/Ham's F12 (pH 7.3; Gibco), 24% normal horse serum (Invitrogen), 1% penicillin-streptomycin (Wako), 1% amphotericin B (Sigma-Aldrich), 1% N2 supplement (Gibco), and additional 10 mM d-glucose (Sigma-Aldrich). The medium was changed every other day. Four days after plating, the cells were trypsinized, stained with 0.04% trypan blue solution, and counted using a Countess Automated Cell Counter (Thermo Fisher Scientific). This assay was carried out in triplicate.
Immunohistochemical Analysis
On day 4 of incubation of the organotypic brain slice cultures, slices containing the cell aggregates were fixed, paraffin embedded, and sectioned at 4-mm thickness. One section was used for H & E staining, and adjacent sections were used for immunohistochemical analysis as follows. After deparaffinization and rehydration of the sections, endogenous peroxidase was quenched with 30-minute incubation in 0.3% (vol/vol) H 2 O 2 in methanol. The sections were then incubated for 20 minutes at room temperature in a blocking buffer consisting of 1% (vol/vol) normal goat serum in PBS containing 0.1% Tween-20, and then incubated overnight at 4°C with polyclonal antibody against GFP (dilution 1:300, Invitrogen) in Tween-20. The EnVision signal enhancement system (Dako) was used to visualize the bound antibodies. The sections were counterstained with hematoxylin and examined under an optical microscope (Biozero-8000).
Gene Expression Microarrays
After the U87 cells were transfected with the negative control or miRNA mimics, the total RNA was isolated from the U87 cells as described above. Complementary RNA was amplified and labeled using Low Input Quick Amp Labeling (Agilent Technologies) and hybridized using a SurePrint G3 Human Gene Expression Microarray v2 8×60 K (Agilent) according to the manufacturer's protocol. All hybridized microarray slides were scanned with an Agilent scanner. Relative hybridization intensities and background hybridization values were calculated using Agilent Feature Extraction Software (9.5.1.1). Microarray data are available from the Gene Expression Omnibus (accession no. GSE83643; http://www.ncbi.nlm.nih.gov/geo/).
Data Analysis and Filter Criteria
The raw signal intensities and flags for each probe were calculated from the hybridization intensities (gProcessedSignal) and spot information (e.g., gIsSaturated) according to the procedures recommended by Agilent (according to the flag criteria of GeneSpring Software, absent is defined as "feature is not positive and significant" and "feature is not above background"; marginal is defined as "feature is not uniform," "feature is saturated," and "feature is a population outlier"; and present is used to define all other criteria). The raw signal intensities of 2 samples were log 2 -transformed and normalized with a quantile algorithm with the preprocessCore library package 7 on Bioconductor software. 10 We selected probes that called the "P" flag in 2 samples. To identify up-or downregulated genes, we calculated Z-scores 36 and ratios (non-log-scaled fold change) from the normalized signal intensities of each probe for comparison of the U87 cells transfected with the negative control and the U87 cells transfected with miRNA mimics. Then, we established criteria for the regulated genes: upregulated genes had a Z-score ≥ 2.0 and ratio ≥ 1.5-fold, and downregulated genes had a Z-score ≤ −2.0 and ratio ≤ 0.66. 28 
Synthesis of cDNA and Determination of Gene Expression by Using Real-Time PCR
After the U87, U251, and LN229 cells were transfected with the negative control or miRNA mimics and the total RNA was isolated from the U87, U251, and LN229 cells as described above, cDNA was synthesized by reverse transcription from the total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. The resulting cDNA was amplified using SYBR Premix Ex Taq II (Takara) under the following conditions: samples were incubated at 95°C for 30 seconds, followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. Real-time PCR was performed using the ABI 7500 Fast Real-Time PCR thermal cycler system (Applied Biosystems). The relative level of mRNA was calculated using cycle time values, which were normalized to the value for b-actin. Primers for human fascin actin-bundling protein 1 (FSCN1) (HA177513, Takara) and b-actin (HA067803, Takara) were used to quantify mRNA expression. To detect hsa-miR-145-5p and -31-5p, the total RNA from the infected cells was re-verse transcribed using a Taqman Reverse Transcription Kit (Applied Biosystems) and the hsa-miR-145-5p-and -31-5p-specific reverse transcription primers (hsa-miR-145-5p, assay ID 002278; hsa-miR-31-5p, assay ID 002279; Applied Biosystems) according to the manufacturer's protocol. Real-time reverse transcription PCR was carried out using a Universal Master Mix (Applied Biosystems) and hsa-miR-145-5p-and −31-5p-specific primers (hsa-miR-145-5p, assay ID 002278; hsa-miR-31-5p, assay ID 002279; Applied Biosystems). For miRNA expression, U6 (assay ID 001973; Applied Biosystems) was used as an endogenous control. Using the 2 -DDCt method, the relative quantification (i.e., fold change) between different samples was calculated. 25 This assay was carried out in triplicate.
Statistical Analysis
For all experiments, 10, 20, or 30 nM negative controls were used for the combinations of 1, 2, or 3 miRNAs, respectively. Differences in the numbers of invading cells and migrating cells and in the relative invasive areas of the cells between the miRNAs and the negative controls were determined using the unpaired t-test. Data are expressed as the mean ± SEM; p < 0.05 was considered to be statistically significant. All statistical analyses were performed using Prism software (version 5.0; GraphPad Software).
Compliance With Ethical Standards
The experimental protocol was approved by the institutional animal care and use committee of Kyushu University. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Results
The Top 5 Most Highly Expressed Cellular and Exosomal miRNAs Were Virtually Identical in Both U87 Cells and hMSCs
The expression levels of the cellular and exosomal miRNAs in the U87 cells and hMSCs were analyzed using reverse transcription PCR (Supplementary Tables S1  and S2 ); hsa-miR-21-5p was the most highly expressed miRNA in all samples. The top 5 most highly expressed cellular miRNAs were also expressed at high levels in the exosomes from both U87 cells and hMSCs. 154-5p, -409-3p, -127-3p, -193a-5p, -145-5p,  143-3p, -196a-5p, and - 
hsa-miR-
31-5p Were More Highly Expressed in hMSC Exosomes Than in U87 Cells
The relative expression ratios of the U87 cellular miRNAs to hMSC exosomal miRNAs were calculated with quantitative real-time reverse transcription PCR. To determine the miRNAs expressed at low levels in the U87 cells, as well as those expressed at high levels in the hMSC exosomes, we selected miRNAs with relative expression ratios less than −3 ([DCq of hMSC exosomal miRNA] -[DCq of U87 cellular miRNA]) (Supplementary Table  S3 ). Of these, hsa-miR-154-5p, -409-3p, -127-3p, -193a-5p, -145-5p, -143-3p, -196a-5p, and -31-5p were highly expressed in the hMSC exosomes, with raw Cq values ≤ 33. -miR-127-3p, -145-5p, or -31-5p 
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Overexpression of hsa
Inhibited the Invasion of U87 Cells
We investigated the effects of the miRNAs hsa-miR-127-3p, -145-5p, and -31-5p on the invasive ability of U87 cells using the Matrigel invasion assay. Overexpression of hsa-miR-127-3p, -145-5p, and -31-5p significantly inhibited the invasion of U87 cells. However, hsa-miR-154-5p, -409-3p, -193a-5p, -143-3p, and -196a-5p had no significant effect on the invasive ability of U87 cells ( Supplementary  Fig. S1 ). To test for synergistic and interactive effects of the miRNAs on invasive ability, various combinations of hsamiR-127-3p, -145-5p, and -31-5p were cotransfected into U87 cells. A single miRNA, a combination of 2 miRNAs, and a combination of 3 miRNAs all inhibited the invasion of U87 cells (Fig. 1A) .
Co-overexpression of hsa-miR-31-5p and -127-3p Improved the Inhibitory Effect of the Overexpression of hsa-miR-31-5p Alone on the Tropism of hMSCs for U87 Cells
Overexpression of the miRNAs that inhibit the invasion of U87 cells may alter the migration ability of hMSCs toward U87 cells. To test this hypothesis, the effect of the overexpression of miRNA on the migration ability of hMSCs was assessed with the Matrigel migration assay. The overexpression of hsa-miR-31-5p alone significantly inhibited the migration of hMSCs toward the U87-conditioned medium. Conversely, the combination of hsa-miR-127-3p and -31-5p significantly increased the tropism of hMSCs for the U87-conditioned medium (Fig. 1B) . The other combinations-hsa-miR-127-3p alone, hsa-miR-145-5p alone, and other combinations of hsa-miR-127-3p, -145-5p, and -31-5p-had no statistically significant effect on the tropism of hMSCs for the U87-conditioned medium.
hMSCs Transfected With hsa-miR-127-3p, -145-5p, and -31-5p Inhibited Invasion by U87 Cells in a Contact-Dependent Manner
Some miRNAs are transferred from host cells to recipient cells via a contact-dependent or a contact-independent mechanism and then alter the function of the recipient cells. 19, 34, 42 To test whether miRNA overexpressed in hMSCs can alter the invasive ability of U87 cells, the invasion of the U87 cells cocultured with the hMSCs that were transfected with the miRNAs was examined with the Matrigel invasion assay. The invasion of the U87 cells cocultured with the hMSCs that were transfected with hsamiR-145-5p alone; hsa-miR-31-5p alone; the combination of hsa-miR-127-3p and -31-5p or of -145-5p and -31-5p; or the combination of hsa-miR-127-3p, -145-5p, and -31-5p was significantly inhibited compared with controls (Fig.  1C) . Of these, the combination of hsa-miR-145-5p and -31-5p reduced the invasive ability of the U87 cells to 60.7% compared with the 20 nM negative control (Fig. 1C and D) . We also examined whether the miRNAs overexpressed in hMSCs affected the invasive ability of the U87 cells in a contact-independent manner. The invasion of the hMSCs by the U87 cells cultured with the conditioned medium obtained from the hMSCs that were transfected with the miRNA was not inhibited (Fig. 1E) .
Effects of hsa-miR-145-5p and -31-5p on U251 and LN229 Cells In Vitro
To test whether the biological effects of hsa-miR-145-5p and -31-5p indicated above were common in GBM cell lines, invasion and migration assays were performed on the alternative GBM cell lines U251 and LN229 because hMSCs exhibited tropism toward both in vivo. 33 The invasion rates of the U251 and LN229 cells, which were cocultured with hMSCs that were cotransfected with these 2 miRNAs, were significantly reduced to 48.1% and 45.1%, respectively, compared with those of the negative controls ( Supplementary Fig. S2A and B). Cotransfection with these 2 miRNAs resulted in a nonsignificant reduction of 49.1% in the migration rate of hMSCs toward the U251-conditioned medium compared with the negative control. On the other hand, the migration rate of hMSCs toward the LN229-conditioned medium was significantly reduced to 58.4% after cotransfection with these 2 miRNAs (Supplementary Fig. S3A and B) . Although the overexpression of hsa-miR-145-5p and -31-5p inhibited the invasion capabilities of the U87, U251, and LN229 cells, both of these miRNAs appeared to affect the tropism of hMSCs toward U251 and LN229 cells. Therefore, we selected U87 cells for the ex vivo invasion assay.
Visual Confirmation of miRNA Transfer From hMSCs to U87 Cells in a Contact-Dependent Manner
To visualize the transfer of miRNAs derived from hMSCs into U87 cells in a contact-dependent manner, the hMSCs were transfected with Alexa555-labeled miR-31-5p ( Fig. 2A) and cocultured with Vybrant DiO-labeled U87 cells (Fig. 2B) . Twenty-four hours after incubation, the Alexa555 signal was detected in the cytoplasm of the U87 cells (Fig. 2C) . The same phenomenon was observed with Alexa555-labeled miR-145-5p (data not shown). Note that a single punctate signal of Alexa555 represented a large cluster of many miRNAs that were taken up through pinocytosis, endocytosis, or other mechanisms 41 and do not represent a single 20-to 22-nucleotide miRNA. The invasion of U87 cells into the organotypic brain slices was first verified in the paraffin sections. The H & E-stained paraffin sections of the organotypic cultures obtained on day 4 revealed viable brain tissue with a wellpreserved cytoarchitecture and viable cell aggregates that consisted of U87 cells coimplanted with hMSCs (Supplementary Fig. S4 upper) . Some invading GFP-expressing U87 cells were observed at a distance from the margin of the cell aggregates ( Supplementary Fig. S4 lower) .
GFP-expressing U87 cells were coimplanted into the organotypic brain slice cultures with the Vybrant DiI-la- 
FIG. 3.
Representative photomicrographs of cell aggregates containing U87 cells and hMSCs implanted into Sprague Dawley rat organotypic brain slices. GFP-expressing U87 cells were coimplanted with Vybrant DiI-labeled hMSCs transfected with hsa-miR-145-5p and -31-5p or the negative control into the striatum of the brain slice. The invasion of U87 cells cotransplanted with hMSCs that were cotransfected with hsa-miR-145-5p and -31-5p was significantly inhibited (lower) compared with the invasion of U87 cells cotransplanted with hMSCs that were transfected with the negative control (upper) at 4 days after implantation. Highmagnification (×200) photomicrographs show a mainly spindle-shaped morphology (upper) for the invasion front of the U87 cells coimplanted with hMSCs that were transfected with the negative control and a mainly rounded morphology (lower) for U87 cells coimplanted with hMSCs that were cotransfected with hsa-miR-145-5p and -31-5p. Bar = 200 µm. beled hMSCs that were transfected with hsa-miR-145-5p and -31-5p or with the negative control (Fig. 3) . Photomicrographs revealed that the invasion by the U87 cells of the cotransplanted hMSCs that were cotransfected with hsamiR-145 and -31-5p was significantly inhibited compared with the negative control at 4 days after implantation. U87 cells coimplanted with hMSCs that were transfected with the negative control invaded widely beyond the distribution of the hMSCs, whereas U87 cells coimplanted with the hMSCs that were cotransfected with hsa-miR-145 and -31-5p remained close to the area with hMSCs.
The relative invasive area of the U87 cells coimplanted with the hMSCs that were cotransfected with hsa-miR-145 and -31-5p (n = 6) decreased by 37.1% compared with the negative control on day 4 (n = 6) (Fig. 4A) . Conversely, we found no significant differences in the migration area of the hMSCs cotransfected with hsa-miR-145-5p and -31-5p compared with the negative control at day 4 (Fig. 4B) .
As shown in high-magnification photomicrographs of the invasion front, U87 cells coimplanted with hMSCs that were transfected with the negative control mainly showed spindle-shaped morphology (Fig. 3 upper) , whereas U87 cells coimplanted with hMSCs that were cotransfected with hsa-miR-145 and -31-5p mainly demonstrated a rounded morphology (Fig. 3 lower) .
Cell proliferation and apoptosis may have been influ-
FIG. 4. A:
Effect of hsa-miR-145-5p and -31-5p on the invasive ability of U87 cells. The relative invasive area of U87 cells coimplanted with hMSCs that were cotransfected with hsa-miR-145-5p and -31-5p (n = 6) was decreased by 37.1% compared with that of the U87 cells coimplanted with hMSCs that were transfected with the negative control (n = 6) on day 4. The area of the cells on the day of implantation was assigned a value of 100%. B: Effect of hsa-miR-145-5p and -31-5p on the tropism of hMSCs. We observed no significant difference in the migration area of the hMSCs cotransfected with hsa-miR-145-5p and -31-5p compared with the area of hMSCs transfected with the negative control on day 4. C: Effect of hsa-miR-145-5p and -31-5p on U87 cell proliferation. Cell proliferation in the cell aggregates was assessed by counting the number of U87 cells and hMSCs transfected with miRNAs or the negative control. We found no significant difference in the total number of cells between cell aggregates containing U87 cells and hMSCs transfected with the NC and aggregates containing U87 cells and hMSCs cotransfected with hsa-miR-145-5p and -31-5p at 4 days after seeding. Data are shown as the means ± SEM (error bars) (n = 6). *p < 0.05. n.s. = not significant.
enced by hsa-miR-145-5p and -31-5p, resulting in the difference in the invasive area of the U87 cells compared with the negative control. To rule out this possibility, we assessed the effect of the hMSCs cotransfected with hsamiR-145-5p and -31-5p on U87 cell proliferation by counting the number of cells in the cell aggregates containing U87 cells and hMSCs transfected with miR-145-5p and -31-5p or the negative control. We found no significant difference in the total number of cells between cell aggregates containing U87 cells and hMSCs transfected with the negative control and those containing U87 cells and hMSCs cotransfected with hsa-miR-145-5p and -31-5p at 4 days after seeding (Fig. 4C ).
Co-overexpression of hsa-miR-145-5p and -31-5p Downregulated FSCN1 Expression in U87 Cells
Whole-genome microarray analysis of the expression changes in 58,341 genes was carried out to identify the gene expression profiles of the U87 cells at 24 hours after transfection with hsa-miR-145-5p and -31-5p. Significant changes in the expression levels of 972 genes were apparent (367 upregulated and 605 downregulated genes). We analyzed the expression profiles of the hsa-miR-145-5p-and hsa-miR-31-5p-targeted genes related to invasion or migration after co-overexpression of hsa-miR-145-5p and -31-5p (Table 1) . 8, 13, 15 Of these, FSCN1 was identified as a significantly downregulated gene (Z-score ≤ −2.0 and ratio ≤ 0.66). To verify the microarray results, we evaluated the gene expression of FSCN1 with reverse transcription PCR. The expression of FSCN1 in the U87 cells cotransfected with hsa-miR-145-5p and -31-5p was significantly suppressed compared with that in the U87 cells transfected with the negative control ( Supplementary Fig. S5 ). The expression of FSCN1 in the U251 cells cotransfected with these 2 miRNAs was not significantly different than the expression observed in the negative control, but FSCN1 expression was significantly suppressed in LN229 cells compared with LN229 cells transfected with the negative control ( Supplementary Fig. S6A and B) .
Changes in the Expression Levels of hsa-miR-145-5p and -31-5p in hMSCs
Changes in the expression levels of hsa-miR-145-5p and -31-5p in hMSCs that had been transfected with these 2 miRNAs were evaluated on days 1, 4, 7, and 11. hsa-miR-145-5p and -31-5p were expressed at 317.0-and 140.4-fold higher levels, respectively, than the miRNA expression level in hMSCs transfected with negative control on day 1. These levels gradually decreased to the control level ( Supplementary Fig. S7 ).
Discussion
In this study, we demonstrated that hMSCs engineered to secrete exosomal hsa-miR-145-5p and -31-5p inhibited the invasion of U87 glioma cells in vitro and ex vivo. Additionally, we showed that hMSCs cotransfected with these 2 miRNAs significantly reduced the in vitro invasion of glioma cell lines U87, U251, and LN229 in a contactdependent manner. Several miRNAs have been reported to affect the invasive ability of glioma cells. 31 miR-145 reduces the invasion of U87 and U373 GBM cells, 23 and mir-31-5p reduces the invasion of U251 GBM cells. 13 The function of miRNAs appears to differ depending on the cell line. Jiang et al. reported that unlike the U87 cells in this study, miR-127-3p promotes the invasion of LN229 and T98G GBM cells. 16 The endogenous expression levels of miRNAs also appear to differ depending on the cell line. LN229 and T98G cells have low endogenous miR-127-3p expression levels, whereas U87 and U251 cells have relatively high endogenous miR-127-3p expression levels. 16 The effect of miRNA overexpression on cell behavior may depend on the endogenous level of miRNA in each cell line. In this study, the effects of the miRNAs that inhibited the invasion of the U87 cells and the migration of hMSCs varied among the different types of miRNAs.
We examined the synergistic and interacting effects of the co-overexpression of miRNAs. As expected, the in vitro Matrigel invasion assay revealed that the co-overexpression of hsa-miR-145-5p and -31-5p inhibited the invasion of U87 cells more than hsa-miR-145-5p or hsa-miR-31-5p alone. Conversely, overexpression of hsa-miR-31-5p alone interfered with the tropism of hMSCs for U87 cells, whereas co-overexpression of hsa-miR-145-5p and -31-5p did not affect the tropism of hMSCs. Unlike U87 cells, the tropism of hMSCs toward U251 and LN229 was inhibited by the overexpression of hsa-miR-145-5p and -31-5p. The tropism of the hMSCs engineered to overexpress hsa-miR-145-5p and -31-5p may be influenced by tumor factors that are secreted in the conditioned medium of the glioma cells. Tumor factors that attract hMSCs, such as interleukin 8, transforming growth factor-b, and neurotrophin 3, are known to vary among glioma cell lines. 6, 38 However, further studies are needed to clarify the mechanism underlying the tropism of hMSCs cotransfected with multiple miRNAs. Nevertheless, our results suggest that the co-overexpression of multiple miRNAs can strengthen the effect of the transfection of a single miRNA depending on the combinations of miRNAs. The transfer of miRNAs from host cells to recipient cells occurs in a contact-dependent and/or a contact-independent manner. 19, 34, 42 Consistent with our results, Lee et al. demonstrated that the effect of synthetic miRNA mimics delivered from hMSCs to U87 cells is weaker, with a contact-independent transfer compared with a contactdependent transfer. 22 This contact-dependent mechanism of miRNA transportation may strengthen the therapeutic advantage of hMSCs regarding tropism for gliomas. Thus, we need to select miRNAs that inhibit the invasion of U87 cells and that promote or do not alter the tropism of hMSCs for U87 cells.
The organotypic brain slice culture model closely resembles the in vivo situation in terms of the cellular microenvironment. 1, 17, 18 The advantage of this model is that cell invasion can be observed over time under fluorescence microscopy or inverted confocal microscopy. 1 In these organotypic brain slice cultures, the effects of hMSCs cotransfected with hsa-miR-145-5p and -31-5p on the in vitro and ex vivo invasive abilities of U87 cells were visually confirmed.
Previous studies have demonstrated that miR-145-5p and -31-5p influence cell proliferation and apoptosis. 8, 15 hsa-miR-145-5p and -31-5p derived from hMSCs may affect the proliferation of U87 cells, thereby resulting in a reduced invasive area of U87 cells. To exclude this possibility, we counted the total numbers of cells in mixed-cell aggregates containing U87 cells and hMSCs transfected with hsa-miR-145-5p and -31-5p and found no significant difference compared with the negative control.
FSCN1 is an actin-bundling protein that plays a key role in maintaining the morphology, motility, and invasive ability of glioma cells.
14,44 FSCN1 expression in human gliomas increases with increasing tumor grade 37 and is correlated with a poorer prognosis.
11 FSCN1 depletion in glioma cells results in a decrease in filopodial formation and cellular protrusion.
14 Downregulation of FSCN expression in glioma cell lines with small interfering RNA is associated with decreased cellular attachment to the extracellular matrix and reduced migration. 14 Vignjevic et al. proposed that FSCN provides the rigidity needed to efficiently push the cell membrane forward. 44 In U87 and LN229 cells, FSCN1 was identified as one of the hsamiR-145-5p-and -31-5p-targeted genes in this study. On the other hand, the expression of FSCN1 in U251 cells was not inhibited when the cells were cotransfected with these 2 miRNAs despite a significant reduction in their invasion ability. The hsa-miR-145-5p-or hsa-miR-31-5p-targeted genes related to invasion or migration (i.e., other than FSCN1) might play a role in determining the invasion characteristics of U251 cells. Further studies are needed to elucidate the mechanisms of gene regulation after cotransfection with multiple miRNAs.
Optimization of the miRNA delivery route is a major challenge for clinical applications. Currently, viral vector systems such as the adeno-associated virus, adenovirus, and retrovirus vectors are widely used for the transfer of miRNA. 24 However, adeno-associated virus and adenovirus vectors are not suitable for the long-term expression of small RNAs, and lentivirus vectors may cause oncogenic mutations. 24 We have shown that hMSCs administered by intravenous or intraarterial injection selectively home toward glioma cells. 33 In this study, we demonstrated that miRNAs were transferred from hMSCs to glioma cells via a contact-dependent mechanism and then altered the invasive function of glioma cells. Altogether, hMSCs have the potential to be used as delivery vehicles for miRNAs to treat gliomas. However, an intratumor injection may be preferable to a systemic injection owing to the tropism of engineered hMSCs toward some types of gliomas caused by the overexpression of miRNAs. For clinical applications, the miRNAs transfected into hMSCs must be expressed stably and persistently. 12 Our results revealed that the transfection process carried out using the mirVana miRNA mimic and Lipofectamine RNAiMAX had only a transient effect. The development of a new transfection method that enables effective, stable, and safe expression of miRNAs is required for the further development of miRNA-based therapies.
Conclusions
This study demonstrated that miRNA overexpression in hMSCs can alter the function of glioma cells via contact-dependent transfer. Co-overexpression of multiple miRNAs may be a useful novel therapeutic strategy. The combination of hsa-miR-145-5p and -31-5p may be a therapeutic candidate for decreasing glioma invasion. Our results suggest that hMSCs may be applied as a delivery vehicle for miRNAs.
